Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Robert M. Dean"'
Autor:
Beth Faiman, Christy J. Samaras, Jason Valent, Matt Kalaycio, Hien D. Liu, Navneet S. Majhail, Rajshekhar Chakraborty, Robert M. Dean, Jack Khouri, Lisa Rybicki, Jacqulyn Tomer
Publikováno v:
American Journal of Hematology. 94:439-445
Response rate and survival in multiple myeloma (MM) has improved in the era of proteasome inhibitors and immunomodulatory drugs. However, most patients eventually relapse with biochemical progression (BP) alone or with clinical features of end-organ
Autor:
Rabi Hanna, Donna Abounader, Navneet S. Majhail, Mayur Narkhede, Brian J. Bolwell, Brad Pohlman, Aaron T. Gerds, Brian T. Hill, Robert M. Dean, Hien D. Liu, Ronald Sobecks, Matt Kalaycio, Betty K. Hamilton, Lisa Rybicki, Deepa Jagadeesh
Publikováno v:
American Journal of Hematology. 92:683-688
Consensus criteria are routinely used to clinically grade acute graft-versus-host disease (GVHD). A histologic grading system for acute GVHD is available, but there are limited data on its correlation with clinical grade and hematopoietic cell transp
Autor:
Robert M. Dean, Matt Kalaycio, Donna Abounader, Hien K. Duong, Lisa Rybicki, Brian J. Bolwell, Brian T. Hill, Betty K. Hamilton, Ronald Sobecks, Navneet S. Majhail, Rabi Hanna, Edward A. Copelan, Housam Haddad
Publikováno v:
American Journal of Hematology. 90:144-148
Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality in allogeneic hematopoietic cell transplantation (HCT) despite current prophylaxis. Methotrexate (MTX) with a calcineurin inhibitor (CNI) is the current standard, howev
Autor:
Ronald Sobecks, Jerome B. Zeldis, Matt Kalaycio, Janice Reed, Aleksandr Lazaryan, Steven Andresen, Rachid Baz, Kimberly Hamilton, Beth Faiman, Mary Ann Karam, Joel Waksman, Gordan Srkalovic, Frederic J. Reu, John Sweetenham, Robert M. Dean, Robert Knight, Becky Habecker, Kellie Bruening, Mohamad A. Hussein
Publikováno v:
American Journal of Hematology. 89:349-354
A previous interim report of MM-011, the first study that combined lenalidomide with anthracycline-based chemotherapy followed by lenalidomide maintenance for relapsed and/or refractory multiple myeloma (RRMM), showed promising safety and activity. W
Autor:
Eric D. Hsi, Robert M. Dean, Brian J. Bolwell, Meagan Effinger, Stephen D. Smith, Amanda L. Maggiotto, Brad Pohlman, John Sweetenham
Publikováno v:
American Journal of Hematology.
Mantle cell lymphoma (MCL) is a unique, recently recognized entity with a variable clinical course [1]. Its historical grouping as an indolent lymphoma belies its common behavior, which is generally aggressive and incurable, with a median survival of